Abstract:Objective:To investigate the clinical characteristics, biological functions and molecular mechanism of polo-like Kinase 4 (Plk4) in gliomas.Methods:We studied the transcriptome data of glioma samples and clinical data of glioma patients in the Cancer Genome Atlas (TCGA) database (689 cases) and the Chinese Glioma Genome Atlas (CGGA) database (693 cases), and transcriptome data of normal brain tissue specimens in the GTEx database (255 cases) were also included. The differences in the expression of Plk4 in glioma specimens and normal brain tissues and glioma specimens of different pathological grades were compared. Log-rank test was used to compare the differences in overall survival between patients with low Plk4 expression and high expression groups. We took human astrocytes, U87, LN229, U251 and A172 cell lines for related research. Small interfering RNA (siRNA) transfection method was used to knock down the expression of Plk4 in U87 and LN229 cells. Real-time fluorescent quantitative polymerase chain reaction was used to detect the expression of Plk4 mRNA. Western blotting was used to detect the expression of Plk4 protein. EdU experiment and Transwell experiment were used to observe the effect of Plk4 on the proliferation, migration and invasion of glioma cells. Twenty 4-week-old female BALB/c-nu nude mice were taken, and U87 cells were injected into the abdomen of mice to prepare glioma xenogeneic tumor-bearing models. The differences in tumor volume and weight were analyzed between the Plk4 knockdown treatment group (intratumor injection of siRNA-Plk4) and the control group (injection of non-sequence Plk4) after 21 d (7 times) of treatment. We took U87 cells with knocked down Plk4, and used proteomics and phosphorylation analysis to explore the molecular mechanism of Plk4's biological function in gliomas.Results:Compared with astrocytes, the expression level of PLk4 mRNA in U87, LN229, U251 and A172 glioma cells was higher. TCGA combined with GTEx database data analysis showed that the expression level of Plk4 mRNA in low-grade glioma and glioblastoma specimens was higher than that in normal brain tissue. Analysis of the samples in the CGGA database showed that the expression level of Plk4 mRNA increased with the increase of the WHO pathological grade. In both databases, the overall survival of patients with high expression of Plk4 was shorter than that of patients with low expression of Plk4. The EdU experiment showed that the EdU positive rate of U87 and LN229 cells that knocked down Plk4 expression was lower than that of nonsense sequence cells. Transwell experiments showed that U87 and LN 229 cells that knocked down Plk4 expression had lower number of gel penetration than nonsense sequence cells. In vivo results showed that the growth rate of subcutaneous tumor in nude mice with Plk4 knockdown was significantly reduced. The differences in the above data were statistically significant (all P<0.01 or 0.05). In proteomics analysis, a total of 428 differentially expressed proteins were identified. In the phosphorylation analysis, a total of 1 180 differentially expressed phosphorylated peptides were identified, corresponding to 728 phosphorylated proteins. Correlation analysis of the results of proteomics and phosphorylation revealed that there were 2 197 proteins associated with proteomics and phosphorylation, of which 66 were only changed at the protein level, only 590 changed at the phosphorylation level, and 25 changed at both protein and phosphorylation levels. The GO function annotation and KEGG pathway enrichment analysis of 590 proteins with only changes at phosphorylation level found that the functions of 590 proteins were mainly protein binding and cadherin binding, etc. The main enrichment pathways were neurotrophic protein signaling pathway and long-term enhancement, etc. Conclusions:Plk4 is highly expressed in brain gliomas, which may be related to the prognosis of patients. Its mechanism may be related to the promotion of the proliferation, migration and invasion of glioma cells through signal pathways such as neurotrophic signaling pathway. Plk4 may be a molecular marker for the diagnosis and prognosis of glioma and a potential target for drug therapy.

Inhibition of PLK4 might enhance the anti‐tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

Polo‑like Kinase4 Promotes Tumorigenesis and Induces Resistance to Radiotherapy in Glioblastoma

Effect of kinase PLK4 on the proliferation of glioma cells in vitro

PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway

Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway

Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling

Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma

Activity of Metabotropic Glutamate Receptor 4 Suppresses Proliferation and Promotes Apoptosis with Inhibition of Gli-1 in Human Glioblastoma Cells.

Study on the function and molecular mechanism of Plk4 in gliomas

PLK4 Initiates Crosstalk Between Cell Cycle, Cell Proliferation and Macrophages Infiltration in Gliomas

Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling

PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway

Phosphatase and Tensin Homolog Reconstruction and Vascular Endothelial Growth Factor Knockdown Synergistically Inhibit the Growth of Glioblastoma

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling

Pten Restoration and Pik3cb Knockdown Synergistically Suppress Glioblastoma Growth in Vitro and in Xenografts

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma

The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells

KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function

PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer

Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma